PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION
Selection of the most effective and safest high-active antiretroviral therapies is a critical issue faced by modern HIV medicine. Authors studied 28 children with HIV infection aged from 3 to 7 divided into two groups administered a combination of two HIV reverse transcriptase nucleoside inhibitors...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Union of pediatricians of Russia,
2010-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_58909cc7da0f404d85b4cf0b59b50e9c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a V.B. Denisenko |e author |
| 700 | 1 | 0 | |a E.N. Simovan'yan |e author |
| 700 | 1 | 0 | |a E.V. Beketova |e author |
| 245 | 0 | 0 | |a PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION |
| 260 | |b Union of pediatricians of Russia, |c 2010-02-01T00:00:00Z. | ||
| 500 | |a 1727-5776 | ||
| 500 | |a 2500-3089 | ||
| 520 | |a Selection of the most effective and safest high-active antiretroviral therapies is a critical issue faced by modern HIV medicine. Authors studied 28 children with HIV infection aged from 3 to 7 divided into two groups administered a combination of two HIV reverse transcriptase nucleoside inhibitors with viral protease nelfinavir inhibitors (n = 13) and lopinavir/ritonavir (n = 15). The subjects in both groups demonstrated a decreased frequency of HIV-associated symptoms and opportunistic infections, positive dynamics of immunological indicators, suppression of HIV replication. When lopinavir/ritonavir was administered, there was more even better dynamics in clinical, immunological and virologic parameters, which allows this medication to be recommended as a antiretroviral therapy for children. Key words: HIV infection, lopinavir/ritonavir, nelfinavir, children. (Pediatric Pharmacology. - 2010; 7(1):62-67) | ||
| 546 | |a RU | ||
| 690 | |a Pediatrics | ||
| 690 | |a RJ1-570 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Педиатрическая фармакология, Vol 7, Iss 1, Pp 62-67 (2010) | |
| 787 | 0 | |n https://www.pedpharma.ru/jour/article/view/1198 | |
| 787 | 0 | |n https://doaj.org/toc/1727-5776 | |
| 787 | 0 | |n https://doaj.org/toc/2500-3089 | |
| 856 | 4 | 1 | |u https://doaj.org/article/58909cc7da0f404d85b4cf0b59b50e9c |z Connect to this object online. |